Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro

Rhea-AI Filing Summary

Bisaro Paul reported acquisition or exercise transactions in this Form 4 filing.

MYRIAD GENETICS INC director Paul Bisaro received an equity award in the form of 59,701 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents a right to one share and will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. After this grant, Bisaro directly holds 157,142 shares of common stock.

Insights

Equity compensation analyst

Routine director RSU grant with time-based vesting.

Director Paul Bisaro received 59,701 restricted stock units under Myriad Genetics' 2026 Employee, Director and Consultant Equity Incentive Plan. The grant is compensation-based, carries no cash outlay, and reflects standard practice for aligning directors with shareholder interests.

The RSUs vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting, creating a roughly one-year service-based vesting horizon. Following the grant, Bisaro holds 157,142 common shares, suggesting this is a meaningful but routine addition to his equity stake.

Insider Trade Summary

Net Buyer: 59,701 shares

Net Buy 1 txn

Insider Bisaro Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	59,701	$0.00	$0.00

Holdings After Transaction: Common Stock — 157,142 shares (Direct)

Footnotes (1)

1. F1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

Key Figures

RSU grant size: 59,701 shares Grant price: $0.0000 per share Post-grant holdings: 157,142 shares +1 more

4 metrics

RSU grant size 59,701 shares Restricted stock units granted to director

Grant price $0.0000 per share No purchase price for RSU award

Post-grant holdings 157,142 shares Common stock held after transaction

Vesting trigger Earlier of 1 year or next annual meeting RSU vesting schedule

Key Terms

restricted stock units, Equity Incentive Plan, vests

3 terms

restricted stock units financial

"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vests financial

"and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/05/2026 - 04:25 PM Accepted by SEC EDGAR 06/05/2026 - 04:24 PM Learn about SEC filing dates

FAQ

What did Myriad Genetics (MYGN) director Paul Bisaro receive in this Form 4?

Paul Bisaro received an award of 59,701 restricted stock units. Each RSU represents a contingent right to one share of Myriad Genetics common stock, granted as director compensation under the company’s 2026 equity incentive plan.

Is Paul Bisaro buying or selling Myriad Genetics (MYGN) shares in this filing?

This filing reports an acquisition through a grant, not a market trade. Bisaro received 59,701 restricted stock units at no purchase price as equity compensation, rather than buying or selling shares on the open market.

When do the 59,701 restricted stock units for MYGN director Bisaro vest?

The 59,701 restricted stock units vest on the earlier of two dates. They vest on the first anniversary of the grant date or on the date of the next annual meeting of stockholders following the grant, whichever occurs first.

How many Myriad Genetics (MYGN) shares does Paul Bisaro hold after this grant?

After this grant, Paul Bisaro holds 157,142 shares of Myriad Genetics common stock directly. This total includes the impact of the newly awarded 59,701 restricted stock units reflected in the Form 4 filing.

Under which plan were the restricted stock units to Paul Bisaro granted?

The 59,701 restricted stock units were granted under Myriad Genetics’ 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. This plan provides equity-based compensation to employees, directors, and consultants using restricted stock units and other awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bisaro Paul

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		59,701(1)	A	$0	157,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

Remarks:

	By: Justin Hunter For: Paul Bisaro	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)